Clinical Trials

AstraZeneca and Forest Laboratories, Inc. announced today that ceftazidime/avibactam (CAZ-AVI) will enter phase III trials to investigate efficacy in treating hospitalised patients with serious Gram-negative bacterial infections including Complicated Intra-Abdominal Infections (cIAI) and Complicated Urinary Tract Infections (cUTI). CAZ-AVI...

First results from a large-scale Phase III trial of RTS,S, published online today in the New England Journal of Medicine (NEJM), show the malaria vaccine candidate to provide young African children with significant protection against clinical and severe...

Acetylon Pharmaceuticals has started treating patients in a three-part Phase 1-2a trial to evaluate ACY-1215 in adult patients suffering from relapsed and relapsed/refractory multiple myeloma. The Phase 1 dose-ranging study expects to investigate ACY-1215...

US based Neurocrine Biosciences has started a second double-blind, placebo controlled, randomized cross-over Phase II trial to evaluate NBI- 98854. The company is developing NBI-98854 to address the unmet medical needs of patients suffering...

Bionor Pharma is set to initiate a double blinded, randomized and placebo-controlled trial to evaluate HIV-vaccine candidate Vacc-4x in combination with Revlimid.Revlimid is indicated as a treatment for multiple myeloma and anemia due to myelodysplastic syndrome linked with a...

The Cohort Review Committee has approved Scancell to further escalate cancer vaccine SCIB1 dose to 4mg from the current 2mg in the Phase I clinical trial and recruitment of the final group of patients as planned. ...

Aeras and the Oxford-Emergent Tuberculosis Consortium (OETC) have commenced a Phase IIb trial to investigate a new experimental tuberculosis vaccine in TB patients with human immunodeficiency virus (HIV) infection. The trial will evaluate the HIV patients...